|
WO1997006121A1
(en)
|
1995-08-04 |
1997-02-20 |
Jennings, Norman, T. |
Compositions and method for controlling odor in organic waste material
|
|
GB9600384D0
(en)
|
1996-01-09 |
1996-03-13 |
Nyfotek As |
Dna glycosylases
|
|
CA2392490A1
(en)
|
1999-11-24 |
2001-05-31 |
Mcs Micro Carrier Systems Gmbh |
Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
|
|
US20040003420A1
(en)
|
2000-11-10 |
2004-01-01 |
Ralf Kuhn |
Modified recombinase
|
|
US20050222030A1
(en)
|
2001-02-21 |
2005-10-06 |
Anthony Allison |
Modified annexin proteins and methods for preventing thrombosis
|
|
US20040115184A1
(en)
|
2001-02-27 |
2004-06-17 |
Smith Harold C |
Methods and compositions for modifying apolipoprotein b mrna editing
|
|
AU2002330714A1
(en)
|
2001-05-30 |
2003-01-02 |
Biomedical Center |
In silico screening for phenotype-associated expressed sequences
|
|
US7300829B2
(en)
|
2003-06-02 |
2007-11-27 |
Applied Materials, Inc. |
Low temperature process for TFT fabrication
|
|
WO2010132092A2
(en)
|
2009-05-12 |
2010-11-18 |
The Scripps Research Institute |
Cytidine deaminase fusions and related methods
|
|
US20110104787A1
(en)
|
2009-11-05 |
2011-05-05 |
President And Fellows Of Harvard College |
Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences
|
|
US20130011380A1
(en)
|
2009-12-18 |
2013-01-10 |
Blau Helen M |
Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming
|
|
US20130109048A1
(en)
|
2010-07-09 |
2013-05-02 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Method for in-vitro monitoring of neuronal disorders and use thereof
|
|
WO2012145384A1
(en)
|
2011-04-20 |
2012-10-26 |
University Of Washington Through Its Center For Commercialization |
Beta-2 microglobulin-deficient cells
|
|
EP2761006B1
(en)
|
2011-09-28 |
2016-12-14 |
Zera Intein Protein Solutions, S.L. |
Split inteins and uses thereof
|
|
CN103088008B
(zh)
|
2011-10-31 |
2014-08-20 |
中国科学院微生物研究所 |
胞苷脱氨酶及其编码基因和它们的应用
|
|
MX2014010185A
(es)
|
2012-02-22 |
2014-11-14 |
Univ Pennsylvania |
Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion.
|
|
US20160289674A1
(en)
|
2012-04-02 |
2016-10-06 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of membrane proteins
|
|
US20150056225A1
(en)
|
2012-04-17 |
2015-02-26 |
University Of Washington Through Its Center For Commercialization |
HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof
|
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
EP3241902B1
(en)
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
US9102936B2
(en)
|
2012-06-11 |
2015-08-11 |
Agilent Technologies, Inc. |
Method of adaptor-dimer subtraction using a CRISPR CAS6 protein
|
|
DK3431497T3
(da)
|
2012-06-27 |
2022-10-10 |
Univ Princeton |
Spaltede inteiner, konjugater og anvendelser deraf
|
|
EP3363902B1
(en)
|
2012-12-06 |
2019-11-27 |
Sigma Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
US20140273230A1
(en)
|
2013-03-15 |
2014-09-18 |
Sigma-Aldrich Co., Llc |
Crispr-based genome modification and regulation
|
|
PL3546572T3
(pl)
|
2013-05-13 |
2024-07-22 |
Cellectis |
Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
|
|
WO2014186686A2
(en)
|
2013-05-17 |
2014-11-20 |
Two Blades Foundation |
Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
|
|
US20140356956A1
(en)
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
|
EP3004370B1
(en)
|
2013-06-05 |
2024-08-21 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
JP2016528890A
(ja)
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用
|
|
WO2015006294A2
(en)
|
2013-07-10 |
2015-01-15 |
President And Fellows Of Harvard College |
Orthogonal cas9 proteins for rna-guided gene regulation and editing
|
|
WO2015021426A1
(en)
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
US9994831B2
(en)
|
2013-12-12 |
2018-06-12 |
The Regents Of The University Of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
|
AU2014361781B2
(en)
|
2013-12-12 |
2021-04-01 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
WO2015092024A2
(en)
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
SG11201609211VA
(en)
|
2014-03-05 |
2016-12-29 |
Nat Univ Corp Univ Kobe |
Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
|
|
MX373460B
(es)
|
2014-03-11 |
2020-04-07 |
Cellectis |
Metodo para generar celulas t compatibles para el trasplante alogenico.
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
WO2015191693A2
(en)
|
2014-06-10 |
2015-12-17 |
Massachusetts Institute Of Technology |
Method for gene editing
|
|
AU2015289644A1
(en)
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
|
JP2017522893A
(ja)
|
2014-07-31 |
2017-08-17 |
セレクティスＣｅｌｌｅｃｔｉｓ |
Ｒｏｒ１特異的多重鎖キメラ抗原受容体
|
|
EP3633032A3
(en)
|
2014-08-28 |
2020-07-29 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
ES2753391T3
(es)
|
2014-10-14 |
2020-04-08 |
Halozyme Inc |
Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
|
|
WO2016061368A1
(en)
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating b-lymphoid malignancies
|
|
US10258697B2
(en)
|
2014-10-29 |
2019-04-16 |
Massachusetts Eye And Ear Infirmary |
Efficient delivery of therapeutic molecules in vitro and in vivo
|
|
WO2016069282A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
|
US10920215B2
(en)
|
2014-11-04 |
2021-02-16 |
National University Corporation Kobe University |
Method for modifying genome sequence to introduce specific mutation to targeted DNA sequence by base-removal reaction, and molecular complex used therein
|
|
MA40921A
(fr)
|
2014-11-05 |
2017-09-12 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
|
|
US11072644B2
(en)
|
2014-11-12 |
2021-07-27 |
Allogene Therapeutics, Inc. |
Inhibitory chimeric antigen receptors
|
|
EA036379B1
(ru)
|
2014-12-12 |
2020-11-02 |
Блубёрд Био, Инк. |
Химерные антигенные рецепторы к bcma
|
|
US10676737B2
(en)
|
2014-12-17 |
2020-06-09 |
Proqr Therapeutics Ii B.V. |
Targeted RNA editing
|
|
CA2971444A1
(en)
|
2014-12-20 |
2016-06-23 |
Arc Bio, Llc |
Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
MA41613A
(fr)
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
|
JP7237449B2
(ja)
|
2015-02-27 |
2023-03-13 |
アイセル・ジーン・セラピューティクス・エルエルシー |
血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
EP3265559B1
(en)
|
2015-03-03 |
2021-01-06 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
|
KR20170137079A
(ko)
|
2015-03-11 |
2017-12-12 |
셀렉티스 |
그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들
|
|
KR20260048600A
(ko)
|
2015-03-27 |
2026-04-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
변형된 t 세포 및 이의 제조 및 사용 방법
|
|
CA2982966C
(en)
|
2015-04-24 |
2024-02-20 |
Editas Medicine, Inc. |
Evaluation of cas9 molecule/guide rna molecule complexes
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
WO2016183438A1
(en)
|
2015-05-14 |
2016-11-17 |
Massachusetts Institute Of Technology |
Self-targeting genome editing system
|
|
CN106011104B
(zh)
|
2015-05-21 |
2019-09-27 |
清华大学 |
利用拆分Cas系统进行基因编辑和表达调控方法
|
|
JP6949728B2
(ja)
|
2015-05-29 |
2021-10-13 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法
|
|
EP3331582A4
(en)
|
2015-05-29 |
2019-08-07 |
Agenovir Corporation |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRANSPLANTATION CELLS
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
TWI813532B
(zh)
|
2015-06-18 |
2023-09-01 |
美商博得學院股份有限公司 |
降低脱靶效應的ｃｒｉｓｐｒ酶突變
|
|
EP4043556B1
(en)
|
2015-06-30 |
2024-02-07 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
|
US11479793B2
(en)
|
2015-07-15 |
2022-10-25 |
Rutgers, The State University Of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
|
US20170020922A1
(en)
|
2015-07-16 |
2017-01-26 |
Batu Biologics Inc. |
Gene editing for immunological destruction of neoplasia
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
WO2017040945A1
(en)
*
|
2015-09-04 |
2017-03-09 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
WO2017048969A1
(en)
|
2015-09-17 |
2017-03-23 |
The Regents Of The University Of California |
Variant cas9 polypeptides comprising internal insertions
|
|
US20180258149A1
(en)
|
2015-09-17 |
2018-09-13 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したＣａｓ９蛋白質
|
|
MX2018005618A
(es)
|
2015-11-05 |
2018-08-01 |
Juno Therapeutics Inc |
Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
|
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
CA2999649A1
(en)
|
2015-11-06 |
2017-05-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of glycogen storage disease type 1a
|
|
CA3006618A1
(en)
|
2015-12-01 |
2017-06-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of alpha-1 antitrypsin deficiency
|
|
EA201891338A1
(ru)
|
2015-12-04 |
2018-12-28 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
ES2949163T3
(es)
|
2016-01-29 |
2023-09-26 |
Univ Princeton |
Inteínas divididas con actividad de corte y empalme excepcional
|
|
KR102438360B1
(ko)
|
2016-03-04 |
2022-08-31 |
에디타스 메디신, 인코포레이티드 |
암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분
|
|
WO2017165862A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
|
TWI773666B
(zh)
|
2016-03-30 |
2022-08-11 |
美商英特利亞醫療公司 |
Crispr/cas 組分之脂質奈米粒子調配物
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
WO2017180993A1
(en)
|
2016-04-14 |
2017-10-19 |
Bluebird Bio, Inc. |
Salvage chimeric antigen receptor systems
|
|
US20200263190A1
(en)
|
2016-04-19 |
2020-08-20 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
CN110382692A
(zh)
|
2016-04-19 |
2019-10-25 |
博德研究所 |
新型crispr酶以及系统
|
|
BR112019000057A2
(pt)
|
2016-07-05 |
2019-04-02 |
The Johns Hopkins University |
composições e métodos com base em crispr/cas9 para o tratamento de degeneração de retina
|
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
|
NZ750256A
(en)
*
|
2016-08-03 |
2026-02-27 |
Dipersio John F |
Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
|
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
US10941402B2
(en)
|
2016-09-01 |
2021-03-09 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded RNA-editing oligonucleotides
|
|
EP3526320A1
(en)
|
2016-10-14 |
2019-08-21 |
President and Fellows of Harvard College |
Aav delivery of nucleobase editors
|
|
KR20240005168A
(ko)
|
2016-11-04 |
2024-01-11 |
2세븐티 바이오, 인코포레이티드 |
항-bcma car t 세포 조성물
|
|
WO2018089664A1
(en)
|
2016-11-11 |
2018-05-17 |
The Regents Of The University Of California |
Variant rna-guided polypeptides and methods of use
|
|
CN107043779B
(zh)
|
2016-12-01 |
2020-05-12 |
中国农业科学院作物科学研究所 |
一种CRISPR/nCas9介导的定点碱基替换在植物中的应用
|
|
AU2017374044B2
(en)
|
2016-12-08 |
2023-11-30 |
Intellia Therapeutics, Inc. |
Modified guide RNAs
|
|
AU2017379073B2
(en)
|
2016-12-22 |
2023-12-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiency
|
|
GB201622044D0
(en)
|
2016-12-22 |
2017-02-08 |
Ucl Business Plc |
T cell-targeted T cells
|
|
EP3559223A1
(en)
|
2016-12-23 |
2019-10-30 |
President and Fellows of Harvard College |
Gene editing of pcsk9
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
WO2018129129A1
(en)
|
2017-01-05 |
2018-07-12 |
Rutgers, The State University Of New Jersey |
Targeted gene editing platform independent of dna double strand break and uses thereof
|
|
JP7717439B2
(ja)
*
|
2017-01-10 |
2025-08-04 |
ザ ジェネラル ホスピタル コーポレイション |
修飾されたｔ細胞及びその使用方法
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2018152197A1
(en)
|
2017-02-15 |
2018-08-23 |
Massachusetts Institute Of Technology |
Dna writers, molecular recorders and uses thereof
|
|
SG11201907870VA
(en)
|
2017-02-28 |
2019-09-27 |
Vor Biopharma Inc |
Compositions and methods for inhibition of lineage specific proteins
|
|
JP2020510038A
(ja)
*
|
2017-03-09 |
2020-04-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
がんワクチン
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
WO2018183888A2
(en)
|
2017-03-31 |
2018-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
|
|
CN106916852B
(zh)
|
2017-04-13 |
2020-12-04 |
上海科技大学 |
一种碱基编辑系统及其构建和应用方法
|
|
WO2018195545A2
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
|
US20200078404A1
(en)
*
|
2017-05-01 |
2020-03-12 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
|
EP3625342B1
(en)
|
2017-05-18 |
2022-08-24 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
WO2018213708A1
(en)
|
2017-05-18 |
2018-11-22 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
WO2018218066A1
(en)
|
2017-05-24 |
2018-11-29 |
The Regents Of The University Of California |
Cmv vaccine and method of making and using the same
|
|
US20200172895A1
(en)
|
2017-05-25 |
2020-06-04 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
|
JP2020525537A
(ja)
|
2017-06-12 |
2020-08-27 |
エモリー ユニバーシティー |
Ｔ細胞抗原標的キメラ抗原受容体（ｃａｒ）、及び細胞療法での使用
|
|
AU2018290843B2
(en)
|
2017-06-26 |
2025-04-24 |
Massachusetts Institute Of Technology |
CRISPR/Cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
|
|
WO2019005886A1
(en)
|
2017-06-26 |
2019-01-03 |
The Broad Institute, Inc. |
CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
|
|
US11168322B2
(en)
|
2017-06-30 |
2021-11-09 |
Arbor Biotechnologies, Inc. |
CRISPR RNA targeting enzymes and systems and uses thereof
|
|
JP7210534B2
(ja)
|
2017-07-12 |
2023-01-23 |
ザ・ボード・オブ・トラスティーズ・オブ・ザ・リーランド・スタンフォード・ジュニア・ユニバーシティ |
Ｈ３ｋ２７ｍ変異を有するがんの処置のための組成物および方法
|
|
US11740242B2
(en)
|
2017-07-14 |
2023-08-29 |
Dana-Farber Cancer Institute, Inc. |
Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
|
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
|
CN118530967A
(zh)
|
2017-08-23 |
2024-08-23 |
通用医疗公司 |
具有改变的PAM特异性的工程化的CRISPR-Cas9核酸酶
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
EP4389889A3
(en)
|
2017-10-06 |
2024-09-04 |
Oregon Health & Science University |
Compositions and methods for editing rna
|
|
KR20250107288A
(ko)
*
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
US11400117B2
(en)
|
2017-12-15 |
2022-08-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inhibiting T cell exhaustion
|
|
CN109957569B
(zh)
|
2017-12-22 |
2022-10-25 |
苏州齐禾生科生物科技有限公司 |
基于cpf1蛋白的碱基编辑系统和方法
|
|
CN112534044A
(zh)
*
|
2018-02-16 |
2021-03-19 |
凯德药业股份有限公司 |
经修饰的多能干细胞及制备和使用方法
|
|
CN112292139B
(zh)
*
|
2018-03-13 |
2024-03-08 |
明尼苏达大学董事会 |
使用Cas9碱基编辑器的淋巴造血改造
|
|
WO2019183000A1
(en)
|
2018-03-19 |
2019-09-26 |
University Of Massachusetts |
Modified guide rnas for crispr genome editing
|
|
EP3781176A4
(en)
|
2018-04-09 |
2022-05-25 |
The Trustees of the University of Pennsylvania |
METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR
|
|
US12473342B2
(en)
|
2018-04-27 |
2025-11-18 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
|
|
JP7558929B2
(ja)
|
2018-05-11 |
2024-10-01 |
ビーム セラピューティクス インク． |
プログラム可能塩基エディターシステムを用いて病原性変異を抑制する方法
|
|
AU2019266327B2
(en)
|
2018-05-11 |
2025-11-06 |
Beam Therapeutics Inc. |
Methods of editing single nucleotide polymorphism using programmable base editor systems
|
|
CN121555430A
(zh)
|
2018-05-11 |
2026-02-24 |
比姆医疗股份有限公司 |
使用可编程碱基编辑器系统取代病原性氨基酸的方法
|
|
EP3797160A1
(en)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Base editors and uses thereof
|
|
CN110616189B
(zh)
|
2018-06-20 |
2022-02-18 |
西安桑尼赛尔生物医药有限公司 |
通用型靶向cd19抗原嵌合受体t细胞的制备及其应用
|
|
CN108753823B
(zh)
|
2018-06-20 |
2022-09-23 |
李广磊 |
利用碱基编辑技术实现基因敲除的方法及其应用
|
|
WO2020010239A1
(en)
|
2018-07-06 |
2020-01-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptor polypeptides and methods of using same
|
|
CN108949825A
(zh)
|
2018-07-30 |
2018-12-07 |
苏州茂行生物科技有限公司 |
一种靶向her2的car-t细胞的制备方法及应用
|
|
AU2019316094B2
(en)
|
2018-08-03 |
2026-02-19 |
Beam Therapeutics Inc. |
Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence
|
|
EP3841203A4
(en)
|
2018-08-23 |
2022-11-02 |
The Broad Institute Inc. |
CAS9 VARIANTS WITH NON-CANONICAL PAM SPECIFICITIES AND THEIR USES
|
|
KR20210055733A
(ko)
|
2018-09-07 |
2021-05-17 |
빔 테라퓨틱스, 인크. |
핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
|
|
CN109295186B
(zh)
|
2018-09-30 |
2023-10-03 |
中山大学 |
一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用
|
|
US20220023348A1
(en)
|
2018-11-28 |
2022-01-27 |
Forty Seven, Inc. |
Genetically modified hspcs resistant to ablation regime
|
|
US20220047637A1
(en)
|
2018-11-29 |
2022-02-17 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
CA3121911A1
(en)
|
2018-12-06 |
2020-06-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Regulatable cell surface receptors and related compositions and methods
|
|
WO2020132327A1
(en)
|
2018-12-19 |
2020-06-25 |
The Trustees Of The University Of Pennsylvania |
Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
|
|
US20220133790A1
(en)
|
2019-01-16 |
2022-05-05 |
Beam Therapeutics Inc. |
Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance
|
|
CN109706121A
(zh)
*
|
2019-01-25 |
2019-05-03 |
苏州茂行生物科技有限公司 |
一种基于碱基编辑的通用型car-t细胞及其制备方法和应用
|
|
KR20210121113A
(ko)
|
2019-01-31 |
2021-10-07 |
빔 테라퓨틱스, 인크. |
비-표적 탈아미노화가 감소된 핵염기 편집기 및 핵염기 편집기를 특성규명하기 위한 분석
|
|
EP3918077A4
(en)
|
2019-01-31 |
2023-03-29 |
Beam Therapeutics, Inc. |
NUCLEOBASE EDITORS WITH REDUCED OFF-TARGET DEAMINATION AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE TARGET SEQUENCE
|
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
|
WO2020168122A1
(en)
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
KR20210126680A
(ko)
|
2019-02-13 |
2021-10-20 |
빔 테라퓨틱스, 인크. |
알파-1 항트립신 결핍증을 치료하기 위한 조성물 및 방법
|
|
AU2020223306A1
(en)
|
2019-02-13 |
2021-08-05 |
Beam Therapeutics Inc. |
Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
|
|
US20220235347A1
(en)
|
2019-02-13 |
2022-07-28 |
Beam Therapeutics Inc. |
Compositions and methods for treating hemoglobinopathies
|
|
US20220127594A1
(en)
|
2019-02-13 |
2022-04-28 |
Beam Therapeutics Inc. |
Compositions and methods for treating glycogen storage disease type 1a
|
|
US20220098593A1
(en)
|
2019-02-13 |
2022-03-31 |
Beam Therapeutics Inc. |
Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
|
|
KR20210139265A
(ko)
|
2019-02-13 |
2021-11-22 |
빔 테라퓨틱스, 인크. |
표적 서열에서 핵염기를 변형하기 위한 아데노신 데아미나제 염기 편집기 및 이의 사용 방법
|
|
EP3924467A1
(en)
|
2019-02-15 |
2021-12-22 |
Editas Medicine, Inc. |
Modified natural killer (nk) cells for immunotherapy
|
|
WO2020176897A1
(en)
|
2019-02-28 |
2020-09-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptors and uses thereof
|
|
JP7654557B2
(ja)
|
2019-03-27 |
2025-04-01 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
CA3139319A1
(en)
|
2019-05-07 |
2020-11-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhancement of polypeptides and chimeric antigen receptors via hinge domains
|
|
WO2020227447A1
(en)
|
2019-05-07 |
2020-11-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptors targeting glypican-2
|
|
US20200370013A1
(en)
|
2019-05-20 |
2020-11-26 |
The Trustees Of The University Of Pennsylvania |
Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors
|
|
WO2020236982A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Aav delivery of nucleobase editors
|
|
US20220387622A1
(en)
|
2019-05-21 |
2022-12-08 |
Beam Therapeutics Inc. |
Methods of editing a single nucleotide polymorphism using programmable base editor systems
|
|
CN118852456A
(zh)
|
2019-05-29 |
2024-10-29 |
Cue生物制药股份有限公司 |
多聚体t细胞调节多肽及其使用方法
|
|
AU2020322021A1
(en)
|
2019-07-30 |
2022-02-10 |
Pairwise Plants Services, Inc. |
Morphogenic regulators and methods of using the same
|
|
KR102258713B1
(ko)
|
2019-07-31 |
2021-05-31 |
한양대학교 산학협력단 |
사이토신 염기교정용 조성물 및 이의 용도
|
|
US20230017979A1
(en)
|
2019-08-29 |
2023-01-19 |
Beam Therapeutics Inc. |
Compositions and methods for non-toxic conditioning
|
|
WO2021042062A2
(en)
|
2019-08-30 |
2021-03-04 |
Joung J Keith |
Combinatorial adenine and cytosine dna base editors
|
|
CN114667149A
(zh)
|
2019-09-09 |
2022-06-24 |
比姆医疗股份有限公司 |
新型核碱基编辑器及其使用方法
|
|
JP7814052B2
(ja)
|
2019-09-17 |
2026-02-16 |
ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー |
標的ゲノム修飾のための高度に効率的なｒｎａ－アプタマー動員媒介性ｄｎａ塩基エディターおよびそれらの使用
|
|
EP4034138A4
(en)
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
KR20220095193A
(ko)
|
2019-10-11 |
2022-07-06 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
조절 가능한 세포 국재화를 위한 재조합 폴리펩티드
|
|
US11591607B2
(en)
|
2019-10-24 |
2023-02-28 |
Pairwise Plants Services, Inc. |
Optimized CRISPR-Cas nucleases and base editors and methods of use thereof
|
|
KR20220110739A
(ko)
|
2019-10-30 |
2022-08-09 |
페어와이즈 플랜츠 서비시즈, 인크. |
유형 v crispr-cas 염기 편집제 및 그의 사용 방법
|
|
US20220380447A1
(en)
|
2019-11-01 |
2022-12-01 |
The Trustees Of The University Of Pennsylvania |
Fibronectin targeting chimeric antigen receptors (cars)
|
|
CN120905142A
(zh)
|
2019-11-20 |
2025-11-07 |
卡瑟里克斯私人有限公司 |
用于提供具有增强功能的免疫细胞的方法
|
|
US20230086199A1
(en)
|
2019-11-26 |
2023-03-23 |
The Broad Institute, Inc. |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
|
EP4076479A4
(en)
|
2019-12-18 |
2024-05-22 |
Editas Medicine, Inc. |
GENETICALLY MODIFIED CELLS FOR THERAPY
|
|
US20210230246A1
(en)
|
2020-01-15 |
2021-07-29 |
The Trustees Of The University Of Pennsylvania |
Use of inhibitory chimeric receptors to prevent t cell-induced blood brain barrier damage
|
|
WO2021158921A2
(en)
|
2020-02-05 |
2021-08-12 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
|
WO2021158999A1
(en)
|
2020-02-05 |
2021-08-12 |
The Broad Institute, Inc. |
Gene editing methods for treating spinal muscular atrophy
|
|
CA3167572A1
(en)
|
2020-02-14 |
2021-08-19 |
Robbie G. MAJZNER |
Chimeric antigen receptors with cd2 activation
|
|
US20230313234A1
(en)
|
2020-03-04 |
2023-10-05 |
Suzhou Qi Biodesign Biotechnology Company Limited |
Improved cytosine base editing system
|
|
AU2021236683A1
(en)
|
2020-03-19 |
2022-11-17 |
Intellia Therapeutics, Inc. |
Methods and compositions for directed genome editing
|
|
WO2021207651A2
(en)
|
2020-04-09 |
2021-10-14 |
Verve Therapeutics, Inc. |
Chemically modified guide rnas for genome editing with cas12b
|
|
EP4179079A1
(en)
|
2020-07-10 |
2023-05-17 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
JP2023534693A
(ja)
|
2020-07-15 |
2023-08-10 |
ライフエディット セラピューティクス，インコーポレイティド |
ウラシル安定化タンパク質並びにその活性断片及びバリアント並びに使用方法
|
|
CA3192224A1
(en)
|
2020-09-11 |
2022-03-17 |
Jyun-Liang LIN |
Base editing enzymes
|
|
TWI910226B
(zh)
|
2020-09-11 |
2026-01-01 |
美商生命編輯治療學公司 |
Ｄｎａ修飾酶及活性片段，及其變異體與使用方法
|
|
WO2022061115A1
(en)
*
|
2020-09-18 |
2022-03-24 |
Vor Biopharma Inc. |
Compositions and methods for cd7 modification
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
US20230383277A1
(en)
|
2020-10-14 |
2023-11-30 |
Beam Therapeutics Inc. |
Compositions and methods for treating glycogen storage disease type 1a
|
|
IT202000028688A1
(it)
|
2020-11-27 |
2022-05-27 |
Consiglio Nazionale Ricerche |
Varianti della citidina deaminasi per l’editazione di basi
|
|
JP2024502348A
(ja)
|
2021-01-05 |
2024-01-18 |
ホライズン・ディスカバリー・リミテッド |
Ｔｒａｃｒ不含 Ｖ型Ｃａｓシステム用のガイドＲＮＡデザインおよび複合体
|
|
WO2022150372A1
(en)
|
2021-01-05 |
2022-07-14 |
Horizon Discovery Ltd. |
Guide rna designs and complexes for type v cas systems
|
|
CA3207144A1
(en)
|
2021-01-05 |
2022-07-14 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
EP4274897A4
(en)
|
2021-01-08 |
2025-03-05 |
The General Hospital Corporation |
GENOMEDITING APPROACHES TO THE TREATMENT OF SPINAL MUSCLE ATROPHY
|
|
WO2022178307A1
(en)
|
2021-02-19 |
2022-08-25 |
Beam Therapeutics Inc. |
Recombinant rabies viruses for gene therapy
|
|
CA3214494A1
(en)
|
2021-03-26 |
2022-09-29 |
Beam Therapeutics Inc. |
Adenosine deaminase variants and uses thereof
|
|
AU2022299551A1
(en)
|
2021-06-23 |
2024-01-18 |
Editas Medicine, Inc. |
Engineered cells for therapy
|
|
US20240327859A1
(en)
|
2021-07-02 |
2024-10-03 |
University Of Maryland, College Park |
Cytidine deaminases and methods of genome editing using the same
|
|
AU2022311013A1
(en)
|
2021-07-16 |
2024-02-08 |
President And Fellows Of Harvard College |
Context-specific adenine base editors and uses thereof
|
|
CA3228879A1
(en)
|
2021-08-16 |
2023-02-23 |
Beam Therapeutics Inc. |
Persistent allogeneic modified immune cells and methods of use thereof
|
|
US20240352439A1
(en)
|
2021-09-03 |
2024-10-24 |
The University Of Chicago |
Polypeptides and methods for modifying nucleic acids
|
|
AU2022349449A1
(en)
|
2021-09-22 |
2024-04-18 |
Verve Therapeutics, Inc. |
Gene editing of pcsk9 or angptl3 and compositions and methods of using same for treatment of disease
|
|
WO2023047338A1
(en)
|
2021-09-24 |
2023-03-30 |
Crispr Therapeutics Ag |
PRODRUG INCORPORATED sgRNA SYNTHESIS
|
|
CA3242360A1
(en)
|
2021-12-10 |
2023-06-15 |
Beam Therapeutics Inc. |
Modified immune cells and methods of using the same
|
|
WO2023125814A1
(zh)
|
2021-12-29 |
2023-07-06 |
华东师范大学 |
腺嘌呤脱氨酶及其应用
|
|
CN119013310A
(zh)
|
2022-02-17 |
2024-11-22 |
正序(上海)生物科技有限公司 |
具有改善的编辑精确度的突变的胞嘧啶脱氨酶
|
|
CN117925585A
(zh)
|
2022-04-07 |
2024-04-26 |
尧唐(上海)生物科技有限公司 |
腺苷脱氨酶、碱基编辑器融合蛋白、碱基编辑器系统及用途
|
|
WO2023227669A2
(en)
|
2022-05-26 |
2023-11-30 |
UCB Biopharma SRL |
Novel nucleic acid-editing proteins
|
|
EP4532697A2
(en)
|
2022-06-03 |
2025-04-09 |
Beam Therapeutics Inc. |
Modified regulatory t cells and methods of using the same
|
|
EP4540378A1
(en)
|
2022-06-20 |
2025-04-23 |
CRISPR Therapeutics AG |
Base editing proteins and uses thereof
|
|
AU2023288909A1
(en)
|
2022-06-23 |
2025-01-09 |
Basf Agricultural Solutions Us Llc |
Diversifying base editing
|
|
WO2024006772A2
(en)
|
2022-06-27 |
2024-01-04 |
Beam Therapeutics Inc. |
Adenosine deaminase base editors and methods for use thereof
|
|
CA3263821A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
ADVANCED CYTOSIN DESAMINASE AND DNA EDITING METHODS USING IT
|
|
CN119998447A
(zh)
|
2022-09-23 |
2025-05-13 |
基础科学研究院 |
新型腺嘌呤脱氨酶变体及使用其进行碱基编辑的方法
|
|
CA3267375A1
(en)
|
2022-09-26 |
2024-04-04 |
Beam Therapeutics Inc. |
SYNTHETIC POLYPEPTIDES AND THEIR USES
|
|
WO2024179426A2
(en)
|
2023-02-28 |
2024-09-06 |
Accuredit Therapeutics (Suzhou) Co., Ltd. |
Deaminases for use in base editing
|
|
WO2024226156A1
(en)
|
2023-04-27 |
2024-10-31 |
University Of Massachusetts |
Cas-embedded cytidine deaminase ribonucleoprotein complexes having improved base editing specificity and efficiency
|
|
WO2024227047A2
(en)
|
2023-04-28 |
2024-10-31 |
Beam Therapeutics Inc. |
Modified guide rna
|
|
CN121889499A
(zh)
|
2023-06-15 |
2026-04-17 |
比姆医疗股份有限公司 |
用于治疗α1-抗胰蛋白酶缺乏症的方法和组合物
|
|
CN117965505A
(zh)
|
2023-06-28 |
2024-05-03 |
微光基因(苏州)有限公司 |
工程化的腺苷脱氨酶及碱基编辑器
|